Exviera dasabuvir: Phase IIIb data

The open-label, international Phase IIIb MALACHITE-I trial in 311 treatment-naive patients with chronic HCV genotype 1 infection without cirrhosis showed that Viekirax ombitasvir/paritaprevir/ritonavir and Exviera with and without ribavirin for 12 weeks led to SVR4 rates

Read the full 360 word article

User Sign In